Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496151 | 0.95 | CA12 (0.32) | CA12CA1CA9KDM5AMAPT | |
| SCHEMBL2497813 | 0.90 | KDM5A (0.37) | CA12CA1CA9KDM5AKDM4C | |
| SCHEMBL347977 | 0.89 | CA12 (0.39) | CA12CA1CA9KDM5AMAPT | |
| SCHEMBL347018 | 0.84 | CA12 (0.34) | CA12CA1CA9MAPTDNM1 | |
| Ether SCHEMBL27695907 | 0.83 | KDM5A (0.39) | CA12CA1CA9KDM5AMAPT | |
| SCHEMBL2494658 | 0.83 | HRH3 (0.31) | — | |
| SCHEMBL16260979 | 0.82 | — | — | |
| SCHEMBL348119 | 0.82 | CA12 (0.33) | CA12CA1CA9MAPT | |
| SCHEMBL7295698 | 0.80 | CA12 (0.37) | CA12CA1CA9KDM5AMAPT | |
| SCHEMBL7295704 | 0.80 | CA12 (0.37) | CA12CA1CA9KDM5AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445502-B2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES PHARMA IRELAND LTD (IE) | 2022-09-28 | — | — | EP | disclosed |
| EP-2072496-B1 | METHOD FOR PRODUCING HIGH-PURITY QUATERNARY AMMONIUM SALT | OTSUKA CHEMICAL CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-8029689-B2 | Method for producing high-purity quaternary ammonium salt | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8029690-B2 | Process for production of highly pure quaternary ammonium salt | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100044617-A1 | Method for producing high-purity quaternary ammonium salt | STELLA CHEMIFA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090272933-A1 | Process for production of highly pure quaternary ammonium salt | STELLA CHEMIFA CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2098518-A1 | PROCESS FOR PRODUCTION OF HIGHLY PURE QUATERNARY AMMONIUM SALT | Otsuka Chemical Co., Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2072496-A1 | METHOD FOR PRODUCING HIGH-PURITY QUATERNARY AMMONIUM SALT | Otsuka Chemical Co., Ltd. (JP) | 2009-06-24 | — | — | EP | disclosed |